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Received August 31, 2011; accepted December 12, 2011AbstractBackground: Positron emission tomography combined with computed tomography (PET-CT) is important in the assessment and workup of lung
cancer staging. However, inconsistencies between clinical image results obtained and pathologic findings of surgical specimens are still very
common, particularly in patients with clinical early stage lung cancer. We sought to clarify the role of PET-CT in predicting mediastinal lymph
node status preoperatively in clinical early stage lung cancer patients.
Methods: The cases were collected retrospectively from January 2008 to February 2009. All patients were good surgical candidates, and
clinically early-stage during the pre-op evaluation, which included CT, PET scan, and cardiopulmonary tests. All patients underwent surgery,
with complete pathological evaluation of mediastinal lymph node (LNs). The pathological status and PET Standardized uptake value (SUV)max
of mediastinal LNs were collected to calculate the ROC curve, and to determine the best cut-off value of PET SUVmax. Other cofactors,
including sex, tumor size, tumor SUVmax, histology type, and lobar distribution, were analyzed utilizing correlation study, Chi-square test, and t-
test for significance.
Results: A total of 83 patients were enrolled into the study. The majority of the cases were in pathological early stage (Stage I: 67.5%, Stage II:
12%). The cut-off point of mediastinal LN SUVmax was 1.6 calculated by receiver operating characteristic (ROC) curve (sensitivity: 40%,
specificity: 88.7%, negative predictive rate: 95.1%). The hilar LN SUVmax was found to have a poor correlation to the final pathologic status of
hilar nodes with insignificant p value (0.487). Tumor SUVmax and increased hilar LN uptake (SUVmax > 2.0) were found to be significantly
correlated with the pathologic status of mediastinal LNs. The false positive rates by PET-CT scan in N1 and N2 nodes were 70% and 78%,
respectively, primarily due to inflammatory process (as anthracosis the leading cause).
Conclusion: Integrated PET-CT is a useful tool for predicting the negativity of mediastinal LN status pre-operatively in clinically early stage
(Stages I and II) lung cancer but may be relatively inaccurate in predicting hilar LN status and largely confounded by false positives caused by
inflammatory process.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Lung cancer is the leading cause of cancer mortality
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doi:10.1016/j.jcma.2012.04.0041.2 million deaths per year.1 In the United States in 2010, there
will have about 222,450 estimated new cases of lung cancer in
both men and women and approximately 157,300 lung cancer-
related deaths.2 The treatment for lung cancer depends on the
histological type of tumor (small cell versus non-small cell)
and its extent (stage). For patients with non-small-cell lung
cancer (NSCLC), accurate staging is crucial to assist the
practitioner and patient to determine a proper treatment plan,
which may include surgery and/or chemoradiotherapy.hinese Medical Association. All rights reserved.
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came into use clinically, several studies have demonstrated its
effectiveness in both improving preoperative assessments, and
decreasing numbers of futile thoracotomies which are con-
ducted.3 The former attempt to integrate both positron emission
tomography and computed tomography (CT), further improving
its diagnostic power and was proven to significantly increasing
the accuracy of staging inNSCLC; it also enhanced the ability of
practitioners to predict stage I and II disease and TandN staging
(compared with PET alone).4 In recent studies, integrated PET-
CT has been proven to be highly specific with a high negative
predictive rate (85 11%).However, the low sensitivity and low
positive predictive rate of PET-CT has also been recognized.5
The sensitivity of PET scanning in staging the mediastinum
was reported to vary from 0.5 to 1.0 in previous studies.6 Those
studies suggest that patients with negative PET-CT results may
be reasonably proceeding to surgery without invasive medias-
tinal staging, due to the high negative predictive rate of PET-CT.
On the other hand, the decision whether or not to perform
amediastinoscopy for thosewho have increase uptake over PET-
CT, and the best cutoff value of Standardized uptake value
(SUV) max still remains in debate.
With the popularization of advanced imaging modalities,
an increasing number of potentially malignant lung lesions
are being discovered. Among these technologies, PET-CT
imaging can play a role in predicting mediastinal lymph
node status pre-operatively, for those who might be patients of
early stage lung cancer without significant mediastinal
lymphadenopathies after CT scan. There have been different
cut-off values of SUVmax of mediastinal lymph node recom-
mended by various studies, ranging from 2.5e5.3.5 We also
noted that, while managing cases with clinically early stage
lung cancer without significant mediastinal lymphadenopa-
thies over CT scan, false positives of mediastinal lymph node
often confounded our interpretation of the preoperative PET-
CT results. Therefore, the aim of this study is to determine
the best cut-off value of SUVmax over PET-CT, utilizing the
data pool in our medical center, and to ascertain cofactors that
may be correlated to the final pathologic status of mediastinal
lymph nodes.
2. Methods
From January 2008 to February 2009, 83 patients with
pathologically proven NSCLC were collected retrospectively
into the study. All patients went through preoperative work-up,
including physical examinations, laboratory tests, CT, PET-CT
scan, and cardiopulmonary testing, and, thereafter, underwent
definitive surgery with radical lymph node dissection. Surgery
and all preoperatives examinations occurred only after
obtaining inform consent from each patient. All patients were
determined to have insignificant mediastinal lymph nodes
(with shortest diameter <1 cm on contrast-enhanced CT scan)
and were clinically staged as Stage I or II. No distant meta-
static lesion was found by pre-operative PET-CT in all 83
patients. Mediastinoscopic biopsy was routinely performed inpatients with significant mediastinal lymphadenopathies over
the preoperative CT scan in our center and was therefore not
performed on the 83 patients enrolled. Complete pathologic
lymph node (LN) staging were obtained in all patients.2.1. PET-CT imagingAll patients were asked to fast at least 6 hours before the
fluorodeoxyglucose-PET examination. Blood sugar levels
were checked and confirmed to be less than 150 mg/dl before
injection of the fluorodeoxyglucose. The PET-CT imaging was
obtained from head to upper portion of the thigh on an inte-
grated PET-CT scanner (Discovery VCT; GE Healthcare,
Waukesha, Wisconsin, USA) 60 minutes after intravenous
injection of 10 mCi (370 MBq) of fluorodeoxyglucose. Low-
dose CT for attenuation correction was performed first with
a 64-slice multidetector computed tomography, which was
followed by the PET scan. The raw data of PET imaging was
reconstructed into a 128  128 matrix with the use of an
iterative reconstruction algorithm (iteration 2, subset 28).2.2. SUV measurementFor quantitative analysis of fluorodeoxyglucose uptake,
SUV was assessed on the Xeleris Workstation (GE Healthcare,
Waukesha, Wisconsin, USA). The maximal SUV of the
primary lung tumors, hilar and mediastinal lymph nodes was
measured by drawing a 1.0-cm diameter region of interest
(ROI) on the slice with the highest fluorodeoxyglucose uptake.
The LNs with SUVmax greater than 2.0 are considered
measurable. For nonmeasurable nodes, we adopted the blood-
pool SUV to represent the uptake of these nodes for the ROC
analysis. In order to calculate the blood-pool SUV, we
randomly selected 20 patients, drew a 1.0-cm ROI in the
center of the superior vena cava on three consecutive slices in
each patient, and recorded the mean SUV in the region of
interest. The mean of the 60 selected ROIs was calculated to
represent the blood-pool SUV, which was calculated as 1.27.
Any nodal uptake over the value of 1.27 will be recorded and
finally compared with the pathology report for plotting the
receiver operating characteristic (ROC) curve.2.3. Surgical resectionAll patients underwent resection through video-assisted
thoracoscopy or a posterolateral thoracotomy. A systematic
approach of LN dissection was carried out in all patients: in
left side lung cancers, LN station 4, 5, 6, and 7 are routinely
dissected; in right side lung cancers, lymph node station 2, 3,
4, and 7 are routinely dissected. Finally, a total number of 281
mediastinal nodal stations were dissected from 83 patients
(average 3.4 nodal station in each patient). All pathologic
specimens were examined by experienced pulmonary pathol-
ogists using standard technique and immunohistochemical
stain. The final pathologic LN staging was compared station
by station with the preoperative PET-CT scan.
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Patient characteristics.
Variable Distribution
Sex (%)
Male 54.2% (n ¼ 45)
Female 45.8% (n ¼ 38)
Age (y)
Mean  SD 66  12
Range 36 w 89
Histology (%)
Adenocarcinoma 81.9% (n ¼ 68)
Squamous cell carcinoma 13.3% (n ¼ 11)
Others 4.6% (n ¼ 4)
Pathologic grade (%)
Well differentiated 9.6% (n ¼ 8)
Moderately differentiated 67.5% (n ¼ 56)
Poorly differentiated 20.5% (n ¼ 17)
Lobar distribution (%)
RUL 33.7% (n ¼ 28)
RML 7.2% (n ¼ 6)
RLL 18.1% (n ¼ 15)
LUL 22.9% (n ¼ 19)
LLL 18.1% (n ¼ 15)
Pathologic staging (%)
Ia 19.3% (n ¼ 16)
Ib 48.2% (n ¼ 40)
Iia 2.4% (n ¼ 2)
Iib 9.6% (n ¼ 8)
IIIa 15.7% (n ¼ 13)
IIIb 3.6% (n ¼ 3)
IV 1.2% (n ¼ 1)
Pathological T staging (%)
T1 26.5% (n ¼ 22)
T2 71.1% (n ¼ 59)
T3 1.2% (n ¼ 1)
T4 1.2% (n ¼ 1)
Pathological N staging (%)
N0 65% (n ¼ 54)
N1 16.9% (n ¼ 14)
N2 18.1% (n ¼ 15)
N3 0% (n ¼ 0)
Tumor size on CT scan (cm)
Mean  SD 3.0  1.5
Range 0.7 w 8.7
Pathologic tumor size (cm)
Mean  SD 3.25  1.73
Range 1.0 w 12.0
SUVmax of primary tumor
Mean  SD 7.7  5.76
Range 0.51 w 31.77
Operation type (%)
Lobectomy 96.4% (n ¼ 80)
Pneumonectomy 2.4% (n ¼ 2)
Lobectomy þ wedge resection 1.2% (n ¼ 1)
CT ¼ computed tomography; LLL ¼ left lower lobe; LUL ¼ left upper lobe;
RLL ¼ right lower lobe; RML ¼ right middle lobe; RUL ¼ right upper lobe;
SD ¼ standard deviation; SUV ¼ standardized uptake value.The software package SPSS v17.0 (SPSS Inc., Chicago, IL,
USA) was used to perform the statistical analysis. The path-
ological status and SUVmax of mediastinal lymph nodes were
collected for calculating ROC curve and determining the cut-
off value of SUVmax. Other co-factors including gender, tumor
size, tumor SUVmax, histology type, lobar distribution were
analyzed with correlation study, Chi-square test, and t-test for
significance. The p values were considered as statistically
significant if <0.05.
3. Results
Our retrospective study included 45 male patients and 38
female patients with age ranges of 36 w 89 and mean (SD)
of 66 (12). All patients received definitive surgery intended
for cure. Among them, 80 received lobectomy (96.4%), two
received pneumonectomy due to encasement of posterior
ascending artery and common basal artery, respectively, and
one received right upper lobe lobectomy and right middle
lobe wedge resection due to lung-to-lung metastasis found
intraoperatively. The final pathologic tumor-node-metastasis
(TNM) staging of our patients was mostly in early stage (Stage
I: 67.5%; Stage II: 12%; Stage III: 19.3%; Stage IV: 1.2%),
and adenocarcinoma was the predominant histological type
among all patients. The false negative rate predicted by pre-
operative CT scan was 18.1% (15 patients was finally found
to have pathological N2 disease among 83 cases). Other
variables including lobar distribution, tumor size, pathologic
grading, and tumor SUVmax were listed in Table 1.
When correlating the relationship between the SUVmax of
mediastinal (N2) and hilar (N1) nodes and their pathological
status, the value of SUVmax was found to be significantly
higher in the pathologically positive mediastinal nodes
(2.18  1.51 vs. 1.46  0.61, p¼ 0.049). However, among
hilar nodes, the differences were not significant (2.20  1.21
vs. 1.84  1.10, p ¼ 0.487), even when excluding the cases
with bilateral hilar uptake (2.04  1.19 vs. 1.65  1.08,
p ¼ 0.317). The cut-off values of SUVmax of N1 and N2 node
calculated by ROC curve were 2.0 and 1.6 (see Fig. 1),
respectively. The sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) calculated
by the cut-off value mentioned above were listed in Table 2.
All factors, including tumor SUVmax, tumor size on CT
image, pathological tumor size, sex, histology, lobar distri-
bution, and pathologic grading of tumor, were correlated with
pathologic hilar and mediastinal LN status. Among all factors,
tumor SUVmax, sex, and increased hilar nodal uptake over
PET-CT (SUVmax > 2.0) were significantly correlated with
mediastinal LN pathologic status (Table 3); only tumor
SUVmax was significantly correlated with hilar lymph node
pathological status (Table 4).
When comparing with cases without increased uptake of
hilar LN on PET-CT, those with increased uptake of hilar LN
(SUVmax > 2.0) were found to possess higher risk of having
pathologically positive N2 nodes [relative risk (RR): 2.5; odds
Fig. 1. The ROC curve for determining the cutoff value (SUVmax) of medi-
astinal LN; at cutoff value of 1.6, the sensitivity and specificity are 40% and
88.9%, respectively. LN, lymph node; ROC curve, receiver operating char-
acteristic curve; SUV ¼ standardized uptake value.
Table 3
Correlation between different factors and mediastinal lymph node pathologic
status.
Pathologically
positive N2
(n ¼ 15)
Pathologically
negative N2
(n ¼ 68)
p value
Tumor SUVmax 9.9  4.2 7.2  5.98 0.007
Tumor size on
preop CT scan (cm)
3.0  1.01 2.99  1.6 0.207
Pathologic tumor size (cm) 3.48  1.34 3.19  1.81 0.542
Age (y) 61  11 67  11 0.442
Sex
Male (%) 26.7 (n ¼ 4) 60.3 (n ¼ 41) 0.018
Female (%) 73.3 (n ¼ 11) 39.7 (n ¼ 27)
Histology
Squamous cell
carcinoma (%)
6.7 (n ¼ 1) 14.7 (n ¼ 10) 0.677
Adenocarcinoma (%) 86.7 (n ¼ 13) 80.9 (n ¼ 55)
Others (%) 6.7 (n ¼ 1) 4.4 (n ¼ 3)
Lobar distribution
RUL (%) 40 (n ¼ 6) 32.4 (n ¼ 22) 0.196
RML (%) 0 (n ¼ 0) 8.8 (n ¼)
RLL (%) 33.3 (n ¼ 5) 14.7 (n ¼ 10)
LUL (%) 6.7 (n ¼ 1) 26.5 (n ¼ 18)
LLL (%) 20 (n ¼ 3) 17.6 (n ¼ 12)
Pathologic grade
Well differentiated (%) 6.7 (n ¼ 1) 10.6 (n ¼ 7) 0.133
Moderately
differentiated (%)
53.3 (n ¼ 8) 72.7 (n ¼ 48)
Poorly differentiated (%) 40 (n ¼ 6) 16.7 (n ¼ 11)
Uptake of hilar LN on PET
SUVmax < 2.0 (%) 40 (n ¼ 6) 67.6 (n ¼ 46) 0.045
SUVmax > 2.0 (%) 60 (n ¼ 9) 32.4 (n ¼ 22)
Ipsilateral uptake of hilar LN on PET (exclude bilateral uptake)
SUVmax < 2.0 (%) 50 (n ¼ 6) 82.8 (n ¼ 48) 0.014
SUVmax > 2.0 (%) 50 (n ¼ 6) 17.2 (n ¼ 10)
CT ¼ computed tomography; LLL ¼ left lower lobe; LUL ¼ left upper lobe;
RLL ¼ right lower lobe; RML ¼ right middle lobe; RUL ¼ right upper lobe;
SD ¼ standard deviation; SUV ¼ standardized uptake value.
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uptake and considering only the cases with ipsilateral hilar LN
uptake, we acquired even higher RR and OR (3.8 and 4.3,
respectively). Fig. 2 is a fine example for the findings
mentioned above.
The false positives of N1 and N2 nodes were calculated and
classified by the pathology report. The common causes of false
positive nodes were anthracosis, reactive hyperplasia, hyali-
nized granuloma, and necrotizing granulomatous inflamma-
tion. The false positive rates by PET-CT scan in N1 and N2
nodes were 70% and 79%, respectively. If cases of bilateral
hilar uptake were excluded, the false positive rate of N1 nodes
will decrease to 53.8%. In both N1 and N2 nodes, the mostTable 2
Sensitivity, specitivity, PPV and NPV of N1 and N2 node by PET-CT scan.
Hilar lymph node
pathologic status
n
Positive Negative
SUVmax of
hilar Lymph node
SUVmax> 2.0 10 21 31
SUVmax< 2.0 8 44 52
n 18 65 83
Mediastinal Lymph node
pathologic status
n
Positive Negative
SUVmax of mediastinal
Lymph node
SUVmax> 1.6 8 29 37
SUVmax< 1.6 12 232 244
n 20 261 281
PPV: 32.3%; NPV: 84.6%; sensitivity: 55.6%; specificity: 67.7%.
PPV: 21.6%; NPV: 95.1%; sensitivity: 40%; specificity: 88.9%.
*PPV: positive predictive rate; NPV: negative predictive rate.common cause of false positives was anthracosis, which was
inflammatory in nature.
4. Discussion
In our study, we use the ROC curve for determining the cutoff
value of SUVmax to most effectively predict the mediastinal LN
status. The SUVmax was calculated to be 1.6, and was compar-
atively lower than those values of 2.5w 5.3 proposed by other
studies.4,5,7,8 Nevertheless, when using this cutoff SUVmax of
1.6 for calculating the sensitivity and specificity (sensitivity:
40%, specificity: 88.7%), we still have results compatible with
other studies, inwhich the specificitywere high and ranged from
85%e94%.4,5,7,8 On the other hand, the sensitivity was variable
and ranged from 40%e91%, which may be caused by the
commonly observed inflammatory change over mediastinal
lymph nodes. The differences in the cutoff SUVmax thresholds
between our studies and others are possibly related to the ratio of
advanced stage lung cancer examined in the different studies.
Table 4
Correlation between different factors and hilar lymph node pathologic status.
Pathologically
positive N1
(n ¼ 18)
Pathologically
negative N1
(n ¼ 65)
p value
Tumor SUVmax 9.0  4.16 7.34  6.1 0.04
Tumor size on
preop CT scan (cm)
3.5  1.63 2.85  1.45 0.241
Pathologic tumor size (cm) 3.77  1.68 3.10  1.73 0.368
Age (y) 63  10 67  12 0.199
Sex
Male (%) 38.9 (n ¼ 7) 58.5 (n ¼ 38) 0.14
Female (%) 61.1 (n ¼ 11) 41.5 (n ¼ 27)
Histology
Squamous cell
carcinoma (%)
11.1 (n ¼ 2) 13.8 (n ¼ 9) 0.365
Adenocarcinoma (%) 77.8 (n ¼ 14) 83.1 (n ¼ 54)
Others (%) 11.1 (n ¼ 2) 3.1 (n ¼ 2)
Lobar distribution
RUL (%) 16.7 (n ¼ 3) 38.5 (n ¼ 25) 0.085
RML (%) 5.6 (n ¼ 1) 7.7 (n ¼ 5)
RLL (%) 38.9 (n ¼ 7) 12.3 (n ¼ 8)
LUL (%) 16.7 (n ¼ 3) 24.6 (n ¼ 16)
LLL (%) 22.2 (n ¼ 4) 16.9 (n ¼ 11)
Pathologic grade
Well differentiated (%) 11.8 (n ¼ 2) 9.4 (n ¼ 6) 0.056
Moderately
differentiated (%)
47.1 (n ¼ 8) 75 (n ¼ 48)
Poorly differentiated (%) 41.2 (n ¼ 7) 15.6 (n ¼ 10)
CT ¼ computed tomography; LLL ¼ left lower lobe; LUL ¼ left upper lobe;
RLL ¼ right lower lobe; RML ¼ right middle lobe; RUL ¼ right upper lobe;
SD ¼ standard deviation; SUV ¼ standardized uptake value.
Fig. 2. (A) Woman aged 66 years with pathology-proven adenocarcinoma over RUL
SUVmax: 4.37, and level 7 node SUVmax: 3.64; the final pathology staging revealed
nodes; (B) Man aged 80 years with pathology-proven squamous cell carcinoma o
SUVmax: 2.85, but no increased uptake over hilar nodes (SUVmax < 2.0); the final p
anthracosis. PET-CT: positron-emission tomography and computed tomography; R
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for 80% of cases, which may explain the lower cutoff value of
N2 nodes comparing to other studies.
The SUVmax of hilar LN was poorly correlated to the final
pathologic status, even when excluding cases of bilateral hilar
uptake. With this result, PET-CT seems to be more useful in
predicting mediastinal rather then hilar LN status. The accu-
racy (number of true positive and true negative divided by total
case number) in predicting N1 and N2 nodal status by PET-CT
in our study is 65% and 85%, respectively. According to the
study of Cerfolio and colleagues,4 the accuracy of PET-CT in
evaluating mediastinal LNs is observed to be higher then the
accuracy in evaluating hilar LNs, which was compatible with
our observations. The overall false positive rate of predicting
hilar nodal status by PET-CT was 70%, and it would decrease
to 53.8% if cases of bilateral hilar uptake were excluded. Most
of the false positive cases are due to anthracosis, followed by
reactive hyperplasia and hyalinized granuloma. These results
can also be observed in other studies, in which LN inflam-
mation is usually the leading cause of false positive results of
PET-CT.9,10 The inflammation can be secondary to infection,
such as tuberculosis, or may be non-infectious or related to
environmental factors, which may be the contributing factor of
the inaccuracy of PET-CT in evaluating hilar LNs.5,11
In terms of predicting N2 nodal status of clinically early
stage lung cancer by PET-CT, a high false positive rate of 79%
was found. The most common cause was also noted to be
anthracosis and hyalinized granuloma. Previous studies have
observed that the type of false positive mediastinal LNs over. Preoperative PET-CT showed tumor SUVmax: 12.8 with ipsilateral hilar node,
pT2N2M0, with both pathologically positive ipsilateral hilar and level 7 lymph
ver RLL. Preoperative PET-CT showed tumor SUVmax: 25 with level 7 node,
athology staging revealed pT2N0M0, pathology report of level 7 lymph nodes:
UL ¼ right upper lobe; SUV ¼ standardized uptake value.
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has been found to be a cause of false positives in Germany,
and histoplasmosis is more prevalent as a cause of false
positives in the southeastern United States. The endemic
granulomatous infection seems to play an important role in
increasing false positive rates of PET-CT. In our experiences
and observations, anthracosis and granulomatous inflamma-
tion are both important causes of false positive in both N1 and
N2 nodal group.
Among all factors which may be correlated to or have
impact on the final pathologic status of mediastinal LNs, only
the value of tumor SUVmax, positive hilar uptake
(SUVmax > 2.0), and sex difference are statistically significant.
In our study, the positive rate of mediastinal LN metastasis is
significantly higher in female group. Meanwhile, we also
observed a higher ratio of adenocarcinoma in the female group
(92.3% in female vs. 68.8% in male, p ¼ 0.007), which is
compatible with the known phenomenon that glandular
differentiation is more popular in women.12e14 The histolog-
ical difference between two sexes may also explain the
increased positive rate of mediastinal LN in female patients
according to the study of Sagawa and colleagues,15 which
noted that lymphatic invasion and LN metastases are common
early in the course of adenocarcinoma. Therefore, we
considered that the influence of sex on the pathologic N2
nodal status may be due to the patient characteristics, and,
thus, does not represent a true phenomenon.
There are still limitations in our study, which primarily
arise from its retrospective nature. PET-CT in itself is an
imaging modality with great variability in its sensitivity and
a relatively high false positive rate. It is also easily confounded
due to inflammatory process and endemic granulomatous
infection, especially in cases with early stage lung cancer. The
high negative predictive rate (95.1%) makes PET-CT a useful
tool in sparing selected patients from unnecessary invasive
mediastinoscopic biopsy. The results garnered from our study
should be further tested with prospective or randomized trial
for clinical application and evaluation of usefulness.
In conclusion, Integrated PET-CT is a useful tool for pre-
dicting the negativity of mediastinal LN status preoperatively
in the clinically early stages of lung cancer (Stages I and II),
but it may be relatively inaccurate in predicting hilar LN status
and be confounded by false positives caused by inflammatory
process. Patients with mediastinal LN uptake <1.6 may go
directly to definitive surgery without a mediastinoscopy. Onthe contrary, for patients with mediastinal LN SUVmax > 1.6
combined with ipsilateral hilar lymph node SUVmax > 2.0, it
is strongly recommended that they receive mediastinoscopic
LN biopsy for an accurate staging.References
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